{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:29:46Z","timestamp":1769113786530,"version":"3.49.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T00:00:00Z","timestamp":1616889600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"publisher","award":["2018YFC1312400"],"award-info":[{"award-number":["2018YFC1312400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"publisher","award":["2018YFC1312401"],"award-info":[{"award-number":["2018YFC1312401"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science and Technology of China, the CAMS Innovation Fund for Medical Science","award":["2016-I2M-2-004"],"award-info":[{"award-number":["2016-I2M-2-004"]}]},{"name":"Ministry of Science and Technology of China, the CAMS Innovation Fund for Medical Science","award":["2017-I2M-2-002"],"award-info":[{"award-number":["2017-I2M-2-002"]}]},{"name":"National Key Technology R&D Program","award":["2015BAI12B02"],"award-info":[{"award-number":["2015BAI12B02"]}]},{"name":"Ministry of Science and Technology of China, the 111 Project from the Ministry of Education of China","award":["B16005"],"award-info":[{"award-number":["B16005"]}]},{"name":"Peking Union Medical College Innovation Fund for Postgraduates","award":["2018-1002-01-12"],"award-info":[{"award-number":["2018-1002-01-12"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The beneficial effect of \u03b2-blocker on heart failure with reduced ejection fraction is well established. However, its effect on the 1-year outcome of heart failure with mid-range ejection fraction (HFmrEF) remains unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We analysed the data of the patients with left ventricular ejection fraction (LVEF) between 40% and 49% in China Patient-centred Evaluative Assessment of Cardiac Events Prospective Heart Failure Study (China PEACE 5p-HF Study), in which patients hospitalized for heart failure from 52 Chinese hospitals were recruited from 2016 to 2018. Two primary outcomes were all-cause death and all-cause hospitalization. The associations between \u03b2-blocker use at discharge and outcomes were assessed by inverse probability of treatment weighting (IPTW)-weighted Cox regression analyses. To assess consistency, IPTW adjusting medications analyses, multivariable analyses and dose-effect analyses were performed. A total of 1035 HFmrEF patients were included in the analysis. The mean age was 65.5\u2009\u00b1\u200912.7\u2009years and 377 (36.4%) were female. The median (interquartile range) of LVEF was 44% (42\u201347%). Six hundred and sixty-one (63.8%) were treated with \u03b2-blocker. Patients using \u03b2-blocker were younger with better cardiac function, and more likely to use renin\u2013angiotensin system inhibitor and mineralocorticoid receptor antagonist. During the 1-year follow-up, death occurred in 84 (12.7%) treated and 85 (22.7%) untreated patients (P\u2009&amp;lt;\u20090.0001); all-cause hospitalization occurred in 298 (45.1%) treated and 188 (50.3%) untreated patients (P\u2009=\u20090.04). After IPTW-weighted adjustment, \u03b2-blocker use was significantly associated with lower risk of all-cause death [hazard ratio (HR): 0.70; 95% confidence interval (CI): 0.51\u20130.96, P\u2009=\u20090.03], but not with lower all-cause hospitalization (HR, 0.92, 95% CI, 0.76\u20131.10, P\u2009=\u20090.36). Consistency analyses showed consistent favourable effect of \u03b2-blocker on all-cause death, but not on all-cause hospitalization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Among patients with HFmrEF, \u03b2-blocker use was associated with lower risk of all-cause death, but not with lower risk of all-cause hospitalization.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvab029","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T20:10:43Z","timestamp":1616789443000},"page":"140-148","source":"Crossref","is-referenced-by-count":8,"title":["\u03b2-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5386-4975","authenticated-orcid":false,"given":"Bin","family":"Wang","sequence":"first","affiliation":[{"name":"National Clinical Research Center for Cardiovascular Diseases, NHC Key Laboratory of Clinical Research for Cardiovascular Medications, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Building C, Fengcunxili 15, Mentougou District, Beijing 102308, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3175-0897","authenticated-orcid":false,"given":"Lihua","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Cardiovascular Diseases, NHC Key Laboratory of Clinical Research for Cardiovascular Medications, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Building C, Fengcunxili 15, Mentougou District, Beijing 102308, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6429-662X","authenticated-orcid":false,"given":"Shuang","family":"Hu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Cardiovascular Diseases, NHC Key Laboratory of Clinical Research for Cardiovascular Medications, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Building C, Fengcunxili 15, Mentougou District, Beijing 102308, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueke","family":"Bai","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Cardiovascular Diseases, NHC Key Laboratory of Clinical Research for Cardiovascular Medications, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Building C, Fengcunxili 15, Mentougou District, Beijing 102308, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Cardiovascular Diseases, NHC Key Laboratory of Clinical Research for Cardiovascular Medications, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Building C, Fengcunxili 15, Mentougou District, Beijing 102308, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2249-688X","authenticated-orcid":false,"given":"Xi","family":"Li","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Cardiovascular Diseases, NHC Key Laboratory of Clinical Research for Cardiovascular Medications, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Building C, Fengcunxili 15, Mentougou District, Beijing 102308, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8840-8638","authenticated-orcid":false,"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Cardiovascular Diseases, NHC Key Laboratory of Clinical Research for Cardiovascular Medications, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Building C, Fengcunxili 15, Mentougou District, Beijing 102308, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6403-4790","authenticated-orcid":false,"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Cardiovascular Diseases, NHC Key Laboratory of Clinical Research for Cardiovascular Medications, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Building C, Fengcunxili 15, Mentougou District, Beijing 102308, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"key":"2022030710595299900_pvab029-B1","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/ejhf.1058","article-title":"What have we learned about heart failure with mid-range ejection fraction one year after its introduction?","volume":"19","author":"Nauta","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2022030710595299900_pvab029-B2","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ejhf.798","article-title":"Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)","volume":"19","author":"Rickenbacher","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2022030710595299900_pvab029-B3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/ejhf.1091","article-title":"Predictors and outcomes of heart failure with mid-range ejection fraction","volume":"20","author":"Bhambhani","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2022030710595299900_pvab029-B4","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022030710595299900_pvab029-B5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ahj.2014.07.008","article-title":"Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population","volume":"168","author":"Cheng","year":"2014","journal-title":"Am Heart J"},{"key":"2022030710595299900_pvab029-B6","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2022030710595299900_pvab029-B7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3389\/fphys.2019.00874","article-title":"Novel mechanisms in heart failure with preserved, midrange, and reduced ejection fraction","volume":"10","author":"Lakhani","year":"2019","journal-title":"Front Physiol"},{"key":"2022030710595299900_pvab029-B8","first-page":"97","volume-title":"JACC Heart Fail","author":"Butler","year":"2014"},{"key":"2022030710595299900_pvab029-B9","doi-asserted-by":"crossref","first-page":"e1916598","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2022030710595299900_pvab029-B10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"2022030710595299900_pvab029-B11","doi-asserted-by":"crossref","first-page":"e025144","DOI":"10.1136\/bmjopen-2018-025144","article-title":"The China Patient-centred Evaluative Assessment of Cardiac Events (PEACE) prospective heart failure study design","volume":"9","author":"Huang","year":"2019","journal-title":"BMJ Open"},{"key":"2022030710595299900_pvab029-B12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"2017 cardiovascular and stroke endpoint definitions for clinical trials","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"key":"2022030710595299900_pvab029-B13","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1681\/ASN.2006040368","article-title":"Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease","volume":"17","author":"Ma","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2022030710595299900_pvab029-B14","volume-title":"Regression Modeling Strategies with Applications to Linear Models, Logistic Regression and Survival Analysis","author":"Fe","year":"2001","edition":"3rd"},{"key":"2022030710595299900_pvab029-B15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/oxfordjournals.aje.a113284","article-title":"Jr. A review of goodness of fit statistics for use in the development of logistic regression models","volume":"115","author":"Lemeshow","year":"1982","journal-title":"Am J Epidemiol"},{"key":"2022030710595299900_pvab029-B16","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis","volume":"35","author":"Austin","year":"2016","journal-title":"Stat Med"},{"key":"2022030710595299900_pvab029-B17","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"2022030710595299900_pvab029-B18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"2022030710595299900_pvab029-B19","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1093\/eurheartj\/ehu131","article-title":"Competing risks analyses: objectives and approaches","volume":"35","author":"Wolbers","year":"2014","journal-title":"Eur Heart J"},{"key":"2022030710595299900_pvab029-B20","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2022030710595299900_pvab029-B21","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacc.2012.03.023","article-title":"Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: a Controlled Trial Investigating Outcomes of Exercise Training) trial","volume":"60","author":"Fiuzat","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2022030710595299900_pvab029-B22","first-page":"109","volume-title":"JACC Heart Fail","author":"Fiuzat","year":"2016"},{"key":"2022030710595299900_pvab029-B23","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/ejhf.945","article-title":"A comprehensive population-based characterization of heart failure with mid-range ejection fraction","volume":"19","author":"Koh","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2022030710595299900_pvab029-B24","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2022030710595299900_pvab029-B25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jchf.2016.10.015","article-title":"Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation: an AF-CHF substudy","volume":"5","author":"Cadrin-Tourigny","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2022030710595299900_pvab029-B26","doi-asserted-by":"crossref","first-page":"e002597","DOI":"10.1161\/CIRCHEARTFAILURE.115.002597","article-title":"\u03b2-blockers in atrial fibrillation patients with or without heart failure: association with mortality in a nationwide cohort study","volume":"9","author":"Nielsen","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2022030710595299900_pvab029-B27","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"key":"2022030710595299900_pvab029-B28","first-page":"21","volume-title":"JACC Heart Fail","author":"Rienstra","year":"2013"},{"key":"2022030710595299900_pvab029-B29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10741-014-9453-8","article-title":"Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis","volume":"20","author":"Bavishi","year":"2015","journal-title":"Heart Fail Rev"},{"key":"2022030710595299900_pvab029-B30","doi-asserted-by":"crossref","first-page":"e002826","DOI":"10.1161\/CIRCHEARTFAILURE.115.002826","article-title":"Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes","volume":"9","author":"Nadruz","year":"2016","journal-title":"Circ Heart Fail"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvab029\/38389665\/pvab029.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/2\/140\/42750793\/pvab029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/2\/140\/42750793\/pvab029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T11:03:09Z","timestamp":1646650989000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/8\/2\/140\/6198106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,27]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,3,27]]},"published-print":{"date-parts":[[2022,2,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvab029","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3]]},"published":{"date-parts":[[2021,3,27]]}}}